Mussa A, Dogliotti L
J Endocrinol Invest. 1979 Jan-Mar;2(1):87-91. doi: 10.1007/BF03349282.
23 women with benign breast disease (fibrocystic disease or fibroadenosis) were treated for three months consecutively with a prolactin inhibitor drug, bromocriptine, at the dose of 2.5 mg every eight hours. Serum prolactin levels were normal before treatment; during treatment prolactin concentrations were significantly suppressed all the day long. 21 out of 23 patients receiving bromocriptine showed marked relief to pain and mammary tension after a few days of treatment; adenomatous of cystic nodules became smaller and softer, often with disappearance of the smaller ones. Two patients failed to respond to treatment. In all positive cases the improvement persisted for at least six months after the end of treatment. No important side effects were observed during the therapy. Our results do not allow any conclusion on the real mechanism of action of bromocriptine in benign breast disease, nevertheless they indicate the possible usefulness of this drug in treating patients with benign breast disease.
23例患有良性乳腺疾病（纤维囊性疾病或纤维腺病）的女性连续三个月接受催乳素抑制剂药物溴隐亭治疗，剂量为每八小时2.5毫克。治疗前血清催乳素水平正常；治疗期间催乳素浓度全天均被显著抑制。23例接受溴隐亭治疗的患者中，21例在治疗几天后疼痛和乳房胀痛明显缓解；腺瘤性或囊性结节变小变软，较小的结节常消失。2例患者治疗无效。在所有阳性病例中，治疗结束后改善情况持续至少六个月。治疗期间未观察到重要的副作用。我们的结果无法就溴隐亭在良性乳腺疾病中的真正作用机制得出任何结论，但它们表明这种药物在治疗良性乳腺疾病患者方面可能有用。
